DempoChem Logo
  1. HomeHome
  2. /ProductsProducts
  3. /Bioactive CompoundsBioactive Compounds
  4. /Anti-Infective AgentsAnti-Infective Agents
  5. /SARS-CoVSARS-CoV
  6. /LeritrelvirLeritrelvir
Chemical structure of CAS 2923310-64-7

Leritrelvir

CAS No.2923310-64-7
MDL No.N/A
MFC31H44F3N5O6
MW639.70
InChI KeyICGMMLTUQDVAST-HEZDJTGRSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT→

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.2923310-64-7
Product NameLeritrelvir
Heavy Atom Count45Rotatable Bond Count10
Atom Stereo Count6Bond Stereo Count0
HBA6HBD4
TPSA153.780 ŲCharge0
Exact Mass639.32437Complexity1168.85
pKa9.613XLogP1.880

Related Articles

Studies related to this compound and its mechanism of action

Lessons learnt from broad-spectrum coronavirus antiviral drug discovery.

Expert opinion on drug discovery • Vol. 19, Issue 9 • 2024
PMID: 39078037PMC: PMC11390334DOI: 10.1080/17460441.2024.2385598

Preclinical evaluation of the SARS-CoV-2 M inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir.

Nature microbiology • Vol. 9, Issue 4 • 2024
PMID: 38553607PMC: PMC10994847DOI: 10.1038/s41564-024-01618-9

Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial.

EClinicalMedicine • Vol. 67 • 2024
PMID: 38188690PMC: PMC10770433DOI: 10.1016/j.eclinm.2023.102359

Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial.

EClinicalMedicine • Vol. 63 • 2023
PMID: 37692076PMC: PMC10484968DOI: 10.1016/j.eclinm.2023.102189

Documentation

Similar Products

  • (1R,2S,5S)-N-[(2S)-4-(3,3-dimethylazetidin-1-yl)-3,4-dioxo-1-[(3S)-2-oxopiperidin-3-yl]butan-2-yl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

    CAS No.2943213-62-3

  • Boceprevir

    CAS No.394730-60-0

  • Nirmatrelvir

    CAS No.2628280-40-8

Your Partner for
Complex Chemistry
logo
  • About Us
  • Perspectives
  • Products
  • Contact
  • Preclinical Development
  • Technologies
  • Custom Synthesis
Ready to start your project?

Provide your target molecule or project specifications to align on a tailored development and scale-up pathway with our scientific team.

START A PROJECT
Westerstraat 10, 3016 DH, Rotterdam, The Netherlands
Westerstraat 10, 3016 DH, Rotterdam, The Netherlands
logo

All products are supplied strictly for research and development use only and are not intended for human or veterinary administration, diagnostic use, or therapeutic use. Preclinical and related services are provided solely for research and development purposes and do not constitute clinical diagnosis, treatment, or veterinary care.

©2026 DempoChem. All Rights Reserved.
DHLFedExUPSPostNL
CLIENT PORTAL|TERMS AND CONDITIONS|PRIVACY POLICY|
  • Products
    • CDMO Compounds
    • API & Candidates
  • Services
    CDMO & Manufacturing
    • Custom Synthesis
    • Process Development
    • Lab To Pilot
    • Commercialization
    • Generic APIs
    CRO
    • Preclinical
    • Pharmacology & Efficacy
    • DMPK & Bioanalysis
    • Toxicology & Safety
    • Disease Models
    Technologies
    • High-Potent
    • Chiral Synthesis
    • Cloud Synthesis
    • Fermentation
    • Flow Chemistry
    • Biocatalysis
    Support
    • Regulatory Support
    • Supply Chain Solutions
  • About
  • Perspectives
  • Contact